Return on Tangible Equity: The amount of net income returned as a percentage of shareholders equity, after subtracting intangible assets, goodwill and preferred equity. Calculated as: Income from Continuing Operations / Tangible Shareholders Equity
Janux Therapeutics, Inc. (JANX) had Return on Tangible Equity of -11.88% for the most recently reported fiscal year, ending 2025-12-31.
| Income Statement Financials | |
$10.00M |
|
$-113.62M |
|
-- |
|
$10.00M |
|
$167.67M |
|
$-157.67M |
|
$44.04M |
|
$-113.62M |
|
$-113.62M |
|
$-113.62M |
|
$-113.62M |
|
$-113.62M |
|
$-113.62M |
|
$-157.67M |
|
$-173.21M |
|
61.97M |
|
61.97M |
|
$-1.83 |
|
$-1.83 |
|
| Balance Sheet Financials | |
$975.89M |
|
$3.85M |
|
$25.68M |
|
$1.00B |
|
$25.00M |
|
-- |
|
$19.75M |
|
$44.74M |
|
$956.82M |
|
$956.82M |
|
$956.82M |
|
60.38M |
|
| Cash Flow Statement Financials | |
$-82.23M |
|
$-300.98M |
|
$4.95M |
|
$431.42M |
|
$53.15M |
|
$-378.27M |
|
$40.22M |
|
-- |
|
-- |
|
| Fundamental Metrics & Ratios | |
39.04 |
|
-- |
|
-- |
|
-- |
|
-- |
|
100.00% |
|
-1576.67% |
|
-1576.67% |
|
-1732.12% |
|
-1136.25% |
|
-1136.25% |
|
$-83.28M |
|
-- |
|
-- |
|
-- |
|
0.01 |
|
-- |
|
-- |
|
-- |
|
-11.88% |
|
|
Return on Tangible Equity |
-11.88% |
-11.34% |
|
-11.88% |
|
$15.85 |
|
$-1.34 |
|
$-1.33 |
|